Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Israel plans to occupy Gaza City, disarm Hamas, and transfer control to Arab forces, raising concerns over humanitarian risks and hostage safety.
Trump administration appeals court order restricting immigration raids in California, raising concerns over enforcement and constitutional protections.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Israel plans to occupy Gaza City, disarm Hamas, and transfer control to Arab forces, raising concerns over humanitarian risks and hostage safety.
Trump administration appeals court order restricting immigration raids in California, raising concerns over enforcement and constitutional protections.